CliffBio
small molecule

BALSALAZIDE DISODIUM

BALSALAZIDE DISODIUM

Loss of exclusivity—loss of exclusivity
CompanyZYDUS LIFESCIENCES GLOBAL FZE

Drug detail

Brand nameBALSALAZIDE DISODIUM
Active ingredientBALSALAZIDE DISODIUM
Strength750MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2023
Marketing statusRX

More from ZYDUS LIFESCIENCES GLOBAL FZE

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BALSALAZIDE DISODIUM patent cliff — loss of exclusivity — | CliffBio